华东医药：2023年年度报告（英文版）.PDF

1、The 2023 Annual Report of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.2023 Annual Report April 2024The 2023 Annual Report of Huadong Medicine Co.,Ltd.2 A Letter to the Shareholders Distinguished shareholders,As time flies,we usher in a new year with endless possibilities.Over the past year,w

2、e have witnessed and experienced profound changes brought by the era.The pharmaceutical industry is marching towards a new track of increasingly healthy and compliant high-quality development driven by continuous pressures it withstands,accelerated industrial clearing due to medical anti-corruption,

3、and continuously increased values of innovative medicines.We are keenly aware that we can tide over the difficulties only by constantly fostering our resilience for development,which will be achieved through our down-to-earth efforts.Since we started our innovation and transformation,we have gradual

4、ly defined development strategies for our four major business segments of pharmaceutical industry,pharmaceutical business,aesthetic medicine and industrial microbiology.Thanks to our consistent practice,we have transformed our innovative R&D system from external introduction to“self-development+intr

5、oduction”step by step and have successfully achieved historic breakthrough in both innovative R&D team building and its capacity,with an industry chain for the complete cycle of innovation medicine R&D fostered.To date,we have established over 100 pharmaceutical product pipelines,including more than

6、 60 pipelines for innovative products,and built the R&D ecology with Hangzhou Zhongmei Huadong Pharmaceutical Co.,Ltd.as the core.In 2023,our constant efforts have been bearing fruits.The Liraglutide Injection was successfully launched,and had its marketing authorization application for diabetes,obe